In August 2025, Novo Nordisk announced that the FDA has approved WEGOVY as the first GLP-1 receptor agonist for adults with Metabolic Dysfunction-associated Steatohepatitis (MASH) who have moderate to advanced fibrosis, excluding cirrhosis, in combination with diet and exercise
Retaturtide (LY3437943) which is an agonist for GLP1R GIP and GCGR demonstrated up to 24% dose-dependent weight loss in phase 2 trials with minimal GI side effects
The cost of replacing a tirzepatide pen is significant, and most healthcare providers understand the urgency
Freshwater snails are the first intermediate hosts, and freshwater fishes belonging to the family Cyprinidae are second intermediate hosts in which larval development occurs
(2) Khavinson V, Diomede F, Mironova E, Linkova N, Trofimova S, Trubiani O, Caputi S, Sinjari B